RecruitingPHASE2, PHASE3NCT06855095

Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial

Studying Germ cell tumor

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
The Netherlands Cancer Institute
Intervention
Somatostatin analog(drug)
Enrollment
39 target
Eligibility
18 years · All sexes
Timeline
2024 – 2027

Study locations (1)

Collaborators

Neuroendocrine Tumor Research Foundation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06855095 on ClinicalTrials.gov

Other trials for Germ cell tumor

Additional recruiting or active studies for the same condition.

See all trials for Germ cell tumor →

← Back to all trials